DiaGenic, Merz deal

Merz received non-exclusive rights to use DiaGenic's panel of 96 blood-based biomarkers for Alzheimer's disease to identify patients for clinical trials. Merz will use the markers to identify patients with mild cognitive impairment (MCI) that may progress to Alzheimer's disease for inclusion in trials of undisclosed Merz compounds. Merz also has an option to license non-exclusive rights to the biomarkers for additional undisclosed uses. Financial terms were not disclosed. ...